METHOD DEVELOPMENT AND VALIDATION OF A HIGHLY SELECTIVE AND SPECIFIC POSITIVE POLARITY ESI-LC-MS/MS METHOD FOR SIMULTANEOUS DETERMINATION OF SEMAGLUTIDE AND CANAGLIFLOZIN IN HUMAN PLASMA

JAGAPATHI RAJU VATSAVAYI; NALANDA BABY REVU

doi:10.22159/ijap.2025v17i3.53379

Authors

JAGAPATHI RAJU VATSAVAYI GITAM School of Pharmacy, GITAM (Deemed to be University), Visakhapatnam-530045, Andhra Pradesh (State), India https://orcid.org/0009-0003-0747-1948
NALANDA BABY REVU GITAM School of Pharmacy, GITAM (Deemed to be University), Visakhapatnam-530045, Andhra Pradesh (State), India https://orcid.org/0000-0002-9314-2459

DOI:

https://doi.org/10.22159/ijap.2025v17i3.53379

Keywords:

Semaglutide, Canagliflozin, Electro spray ionization, Method validation, Mass spectrometer

Abstract

Objective: To develop a method capable of simultaneous estimation and quantification of semaglutide and canagliflozin being studied as a potential combination therapy for treating Diabetes.

Materials: An elaborate protein precipitation extraction technique used verapamil as internal standards for semaglutide and canagliflozin. The two compounds were separated on a Zorbax C18 (50 mm x 2.1 mm, 5 µ Particle size) column, with a positive polarity Electro Spray Ionization (ESI) on a Liquid chromatograph with Tandem Mass Spectrometry (LC-MS/MS) instrument. The estimation was through a Multiple Reaction Monitoring (MRM) method, and a gradient program utilizing Acetonitrile and 5 mmol Ammonium formate with 0.1% formic acid as mobile phases to achieve a separation in 2.5 min.

Results: The method established was performing linearly over a working range of 1.00 to 1000 ng/ml for both semaglutide (r²>0.98) and canagliflozin (r²>0.98) in human plasma. The specificity, selectivity, precision, accuracy, recovery, matrix effects and stability were within acceptable limits. The stability was established under various conditions as necessitated by the guideline on Bioanalytical method validation as mentioned in International Council for Harmonisation of Technical Requirements of Pharmaceuticals for Human Use (ICH) M10.

Conclusion: This highly selective and sensitive method where 1.00 ng/ml was employed for semaglutide and canagliflozin as the Lower Limit of Quantification (LLOQ) can be utilized for estimation in human plasma will facilitate the further application to pharmacokinetic, bioequivalence and population pharmacokinetics studies for combination of these two drugs in pharmaceutical dosage forms.

References

Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834-44. doi: 10.1056/NEJMoa1607141, PMID 27633186.

Goldenberg RM, Steen O. Semaglutide: review and place in therapy for adults with type 2 diabetes. Can J Diabetes. 2019;43(2):136-45. doi: 10.1016/j.jcjd.2018.05.008, PMID 30195966.

Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ. Glucagon-like peptide-1 receptor signaling modulates beta-cell apoptosis. J Biol Chem. 2003;278(1):471-8. doi: 10.1074/jbc.M209423200, PMID 12409292.

Meier JJ. Efficacy of semaglutide in a subcutaneous and an oral formulation. Front Endocrinol (Lausanne). 2021;12:645617. doi: 10.3389/fendo.2021.645617, PMID 34248838, PMCID PMC8269445.

Jensen L, Helleberg H, Roffel A, van Lier JJ, Bjørnsdottir I, Pedersen PJ. Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species. Eur J Pharm Sci. 2017;104:31-41. doi: 10.1016/j.ejps.2017.03.020, PMID 28323117.

Marbury TC, Flint A, Jacobsen JB, Derving Karsbøl J, Lasseter K. Pharmacokinetics and tolerability of a single dose of semaglutide, a human glucagon-like peptide-1 analog, in subjects with and without renal impairment. Clin Pharmacokinet. 2017;56(11):1381-90. doi: 10.1007/s40262-017-0528-2, PMID 28349386, PMCID PMC5648736.

Overgaard RV, Navarria A, Ingwersen SH, Baekdal TA, Kildemoes RJ. Clinical pharmacokinetics of oral semaglutide: analyses of data from Clinical Pharmacology trials. Clin Pharmacokinet. 2021;60(10):1335-48. doi: 10.1007/s40262-021-01025-x, PMID 33969456, PMCID PMC8505367.

Jensen L, Kupcova V, Arold G, Pettersson J, Hjerpsted JB. Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment. Diabetes Obes Metab. 2018;20(4):998-1005. doi: 10.1111/dom.13186, PMID 29205786, PMCID PMC5873441.

Baekdal TA, Thomsen M, Kupcova V, Hansen CW, Anderson TW. Pharmacokinetics, safety, and tolerability of oral semaglutide in subjects with hepatic impairment. J Clin Pharmacol. 2018;58(10):1314-23. doi: 10.1002/jcph.1131, PMID 29693715, PMCID PMC6175428.

Kute SA, Chothave MS, Rote PB, Kapadnis AA, Kale VV. Exploring the unintended consequences of misuse of wegovy and ozempic in weight management: a comprehensive review. Int J Pharm Pharm Sci. 2024;16(6):10-3. doi: 10.22159/ijpps.2024v16i6.50611.

Lee TS, Park EJ, Choi M, Oh HS, An Y, Kim T. Novel LC-MS/MS analysis of the GLP-1 analog semaglutide with its application to pharmacokinetics and brain distribution studies in rats. J Chromatogr B Analyt Technol Biomed Life Sci. 2023 Apr 15;1221:123688. doi: 10.1016/j.jchromb.2023.123688, PMID 36989942.

Kapitza C, Nosek L, Jensen L, Hartvig H, Jensen CB, Flint A. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. J Clin Pharmacol. 2015;55(5):497-504. doi: 10.1002/jcph.443, PMID 25475122, PMCID PMC4418331.

Gumieniczek A, Berecka A. Analytical tools for determination of new oral antidiabetic drugs, glitazones, gliptins, gliflozins, and glinides, in bulk materials, pharmaceuticals, and biological samples. Open Chem. 2016;14(1):215-42.

DeFronzo RA, Ferrannini E, Groop L, Henry RR, Herman WH, Holst JJ. Type 2 diabetes mellitus. Nat Rev Dis Primers. 2015;1:15019. doi: 10.1038/nrdp.2015.19, PMID 27189025.

Scheen AJ, Paquot N. Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes. Diabetes Metab. 2013;39(3):179-90. doi: 10.1016/j.diabet.2013.02.006, PMID 23528671.

Sarkar S, Sadhu S, Roy R, Tarafdar S, Mukherjee N, Sil M. Contemporary drifts in diabetes management. Int J App Pharm. 2023;15(2):1-9. doi: 10.22159/ijap.2023v15i2.46792.

Van der Aart-van der Beek AB, Wessels AM, Heerspink HJ, Touw DJ. Simple, fast and robust LC-MS/MS method for the simultaneous quantification of canagliflozin, dapagliflozin and empagliflozin in human plasma and urine. J Chromatogr B Analyt Technol Biomed Life Sci. 2020 Sep 1;1152:122257. doi: 10.1016/j.jchromb.2020.122257, PMID 32663790.

Wattamwar T, Mungantiwar A, Gujar S, Pandita N. Development of LC-MS/MS method for simultaneous determination of canagliflozin and metformin in human plasma and its pharmacokinetic application in Indian population under fast and fed conditions. J Chromatogr B Analyt Technol Biomed Life Sci. 2020 Oct 1;1154:122281. doi: 10.1016/j.jchromb.2020.122281, PMID 32763846.

Kobuchi S, Yano K, Ito Y, Sakaeda T. A validated LC-MS/MS method for the determination of canagliflozin, a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, in a lower volume of rat plasma: application to pharmacokinetic studies in rats. Biomed Chromatogr. 2016 Oct;30(10):1549-55. doi: 10.1002/bmc.3720, PMID 26989857.

US Food and Drug Administration. Bioanalytical method validation: guidance for industry. Silver Spring, MD; 2018.

ICH guideline M10 on Bioanalytical method validation and study sample analysis; 2023.

Matuszewski BK, Constanzer ML, Chavez Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem. 2003;75(13):3019-30. doi: 10.1021/ac020361s, PMID 12964746.

Bhatt D, Rajkamal BA. Validated LC-MS/MS method for pharmacokinetic study of canagliflozin in healthy rabbits. Int J Pharm Pharm Sci. 2018;10(2):80-6. doi: 10.22159/ijpps.2018v10i2.23245.